Nonconventional Fluorescent Hyperbranched Polymer Dots as Skin Nanocarriers Constructed from an Olefinic Aliphatic AB2-Type Monomer
Source abstract
Abstract
We constructed an olefinic aliphatic AB2 monomer (π-AB2) for the synthesis of a nonconventional fluorescent hyperbranched polymers (π-HBPs) through self-polymerization. We obtained π-AB2 from N-(3-aminopropyl)diethanolamine and maleic anhydride in three steps with a total yield of 79%. The π-HBPs possessed hyperbranched poly(amido acid) structures with internal alkene moieties, branched amino groups, and carboxyl terminal units. With their nonconjugated hyperbranched structures, the π-HBPs functioned as water-soluble polymer dots. Inter- and intramolecular hydrogen bonding in the π-HBPs resulted in a physically cross-linked structures displaying nonconventional fluorescence. This fluorescence arose from spatial conjugation at the molecular level, leading to clustering-induced emission with the lone pairs of electrons and the π-electrons interacting in a narrow confinement space. The emission of π-HBP 03 occurred at 460 nm upon excitation of 390 nm, with quantum yields of 13.5 and 7.5% at pH 7 and 3, respectively. From an examination of the relationship between chemical structure and photoluminescence, we found that the fluorescence emissions of the HBP without internal alkene moieties and π-HBP 03 (with internal alkene moieties) were 395 and 460 nm, respectively (a red-shift of 65 nm when removing the olefinic units). The self-assembly of π-HBP 03 in aqueous solution produced nanosized (ca. 9.1 nm) particles, as determined through dynamic light scattering. π-HBP 03 is noncytotoxic, with a cell viability of >90% at 1500 μg mL–1. When applied to percutaneous absorption mouse skin, the penetration ability of the π-HBPs increased in various time profiles according to the cluster size and nanostructure of the polymer dots. When we incubated HaCaT cells with π-HBP 03 for 24 h, confocal microscopy revealed that π-HBP 03 became located within the cells. Furthermore, assays revealed that π-HBP 03 displayed effective antioxidant abilities when employed at concentrations of 0.6 and 1.5 mg mL–1.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Carbon and Quantum Dots Applications · Luminescence and Fluorescent Materials · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Aesthetic Medical Center, China Medical University Hospital, Taichung406040, Taiwan
School of Medicine, China Medical University, Taichung406040, Taiwan
Department of Cosmeceutics, China Medical University, Taichung406040, Taiwan
Department of Bioinformatics and Medical Engineering, Asia University, Taichung413305, Taiwan
Department of Chemical Engineering, National Chung Hsing University, Taichung402202, Taiwan
Funding
National Science Council · China Medical University
References (47)
Show source-provided references
1. 10.1039/D0QM00626B10.1039/D0QM00626B ↗
2. 10.1021/acsomega.0c0470010.1021/acsomega.0c04700 ↗
3. 10.1002/anie.20220438310.1002/anie.202204383 ↗
4. 10.1016/j.jphotochem.2018.06.03110.1016/j.jphotochem.2018.06.031 ↗
5. 10.1021/acs.macromol.9b0026310.1021/acs.macromol.9b00263 ↗
6. 10.1002/ange.20191659110.1002/ange.201916591 ↗
7. 10.1016/j.mattod.2019.08.01010.1016/j.mattod.2019.08.010 ↗
8. 10.1021/acs.jpcb.0c0660610.1021/acs.jpcb.0c06606 ↗
9. 10.1002/pola.2875410.1002/pola.28754 ↗
10. 10.1039/D0PY01285H10.1039/D0PY01285H ↗
11. 10.1039/C7ME00118E10.1039/C7ME00118E ↗
12. 10.1002/advs.20200429910.1002/advs.202004299 ↗
13. 10.1002/smll.20200503510.1002/smll.202005035 ↗
14. 10.1021/jacs.8b0605110.1021/jacs.8b06051 ↗
15. 10.1016/j.scib.2020.12.01510.1016/j.scib.2020.12.015 ↗
16. 10.1021/acs.biomac.8b0012310.1021/acs.biomac.8b00123 ↗
17. 10.1002/agt2.16910.1002/agt2.169 ↗
18. 10.1021/jacsau.1c0031110.1021/jacsau.1c00311 ↗
19. 10.1016/j.jlumin.2019.11658210.1016/j.jlumin.2019.116582 ↗
20. 10.3389/fchem.2019.0044710.3389/fchem.2019.00447 ↗
21. 10.1016/j.progpolymsci.2018.09.00410.1016/j.progpolymsci.2018.09.004 ↗
22. 10.1039/C7PY00154A10.1039/C7PY00154A ↗
23. 10.1021/acsomega.1c0134310.1021/acsomega.1c01343 ↗
24. 10.1021/acs.est.0c0070210.1021/acs.est.0c00702 ↗
25. 10.1021/acsomega.1c0553710.1021/acsomega.1c05537 ↗
26. 10.1021/acssuschemeng.0c0782510.1021/acssuschemeng.0c07825 ↗
27. 10.1021/acs.biomac.1c0139610.1021/acs.biomac.1c01396 ↗
28. 10.1016/j.cej.2021.13214210.1016/j.cej.2021.132142 ↗
29. 10.1039/C6PY00409A10.1039/C6PY00409A ↗
30. 10.1039/C6PY00986G10.1039/C6PY00986G ↗
31. 10.1016/j.polymer.2012.12.01310.1016/j.polymer.2012.12.013 ↗
32. 10.1016/j.nantod.2014.09.00410.1016/j.nantod.2014.09.004 ↗
33. Agostinis P. · CA: A Cancer Journal for Clinicians · 2011 · 61 · 250
34. 10.1039/c2jm30658a10.1039/c2jm30658a ↗
35. 10.1016/j.carbon.2020.06.02410.1016/j.carbon.2020.06.024 ↗
36. Koutsogiannis P. · Advances in Physics: X · 2020 · 5 · 1758592
37. 10.1021/acs.jpclett.9b0138410.1021/acs.jpclett.9b01384 ↗
38. 10.1039/D1RA01318A10.1039/D1RA01318A ↗
39. 10.1186/s12906-018-2308-410.1186/s12906-018-2308-4 ↗
40. 10.1155/2013/69687910.1155/2013/696879 ↗
41. 10.1039/C6NR01909A10.1039/C6NR01909A ↗
42. 10.1039/D1QM00808K10.1039/D1QM00808K ↗
43. 10.1007/s12274-014-0644-310.1007/s12274-014-0644-3 ↗
44. 10.1002/anie.20150495110.1002/anie.201504951 ↗
45. 10.1021/acs.molpharmaceut.0c0015410.1021/acs.molpharmaceut.0c00154 ↗
46. 10.3389/fbioe.2020.0057510.3389/fbioe.2020.00575 ↗
47. 10.3762/bjnano.9.5110.3762/bjnano.9.51 ↗